WuXi PharmaTech Earnings: Everything You Must Know Now

  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

WuXi PharmaTech (Cayman) Inc. (NYSE:WX) delivered a profit and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company.

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

WuXi PharmaTech (Cayman) Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share increased 6.06% to $0.35 in the quarter versus EPS of $0.33 in the year-earlier quarter.

Revenue: Rose 11.75% to $131.9 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: WuXi PharmaTech (Cayman) Inc. reported adjusted EPS income of $0.35 per share. By that measure, the company beat the mean analyst estimate of $0.31. It beat the average revenue estimate of $130.02 million.

Quoting Management: “I am pleased to announce that WuXi began 2013 with a solid first quarter,” said Dr. Ge Li, Chairman and Chief Executive Officer. “We achieved 11.7% year-over-year revenue growth, 7.2% GAAP diluted EPS growth, and 7.5% non-GAAP diluted EPS growth in the quarter, exceeding our previous guidance in all three measures. This result gives us confidence to reconfirm our guidance for full-year 2013.”

Key Stats (on next page)…

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business